FOLH1 and pachyonychia congenita: Thus, recent research has assessed the antitumor efficacy by developing a construct comprising miR-34a, known for inhibiting PC cell proliferation, a targeting ligand DUPA (2-[3-(1,3-dicarboxy propyl) ureido] pentanedioic acid) specifically for PSMA, and nigericin as endosomal escape agent.